Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Noa Eliakim-Raz; Yaara Leibovici-Weisman; Amos Stemmer; Asaf Ness; Muhammad Awwad; Nassem Ghantous; Salomon M Stemmer

doi:10.1001/jama.2021.19885

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

JAMA. 2021 Dec 7;326(21):2203-2204. doi: 10.1001/jama.2021.19885.

Authors

Noa Eliakim-Raz¹, Yaara Leibovici-Weisman¹, Amos Stemmer², Asaf Ness¹, Muhammad Awwad¹, Nassem Ghantous¹, Salomon M Stemmer¹

Affiliations

¹ Rabin Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel.
² Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel.

Abstract

This study assesses antispike (anti-S) IgG antibody titers before and after a third BNT162b2 dose (booster) in individuals aged 60 years and older in Israel.

MeSH terms

Aged
Aged, 80 and over
Antibodies, Viral / blood*
Antibodies, Viral / immunology
BNT162 Vaccine
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / administration & dosage*
COVID-19 Vaccines / genetics
COVID-19 Vaccines / immunology
Female
Humans
Immunoglobulin G / blood*
Immunoglobulin G / immunology
Male
Middle Aged
RNA, Messenger / administration & dosage
RNA, Messenger / blood
RNA, Messenger / immunology*
RNA, Viral / administration & dosage
RNA, Viral / genetics
RNA, Viral / immunology*
SARS-CoV-2 / genetics
SARS-CoV-2 / immunology*
Treatment Outcome

Substances

Antibodies, Viral
COVID-19 Vaccines
Immunoglobulin G
RNA, Messenger
RNA, Viral
BNT162 Vaccine